Gilead's expansion beyond HIV therapies will surprise many investors.

– Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc., (Nasdaq: GILD) today announced ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after ...

In the latest close session, Gilead Sciences (GILD) was down 3.72% at $129.83. The stock's performance was behind the S&P 500 ...

Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall ...

Shares of Gilead Sciences Inc. GILD slipped 3.72% to $129.83 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.42% to 7,575.39 ...

HSBC upgraded Gilead Sciences Inc. GILD on Monday, citing that the consensus is ‘too pessimistic’ in its assumptions of ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...

Shares of Gilead Sciences Inc. GILD advanced 5.21% to $136.36 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.45% to ...